83 FR 3748 - Final Effect of Designation of a Class of Employees for Addition to the Special Exposure Cohort
DEPARTMENT OF HEALTH AND HUMAN SERVICES Federal Register Volume 83, Issue 18 (January 26, 2018)
Federal Register Volume 83, Issue 18 (January 26, 2018)
| Page Range | 3748-3749 | |
| FR Document | 2018-01449 |
[Federal Register Volume 83, Number 18 (Friday, January 26, 2018)] [Notices] [Pages 3748-3749] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-01449] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Final Effect of Designation of a Class of Employees for Addition to the Special Exposure Cohort AGENCY: National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services (HHS). ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: HHS gives notice concerning the final effect of the HHS decision to designate a class of employees from the Idaho National Laboratory in Scoville, Idaho, as an addition to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000. FOR FURTHER INFORMATION CONTACT: Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, NIOSH, 1090 Tusculum Avenue, MS C-46, Cincinnati, OH 45226-1938, Telephone 877-222-7570. Information requests can also be submitted by email to [email protected]. SUPPLEMENTARY INFORMATION: Authority: 42 U.S.C. 7384q(b). 42 U.S.C. 7384l(14)(C). On November 22, 2017, as provided for under 42 U.S.C. 7384l(14)(C), the Acting Secretary of HHS designated the following class of employees as an addition to the SEC: All employees of the Department of Energy, its predecessor agencies, and their contractors and subcontractors who worked at the Idaho National Laboratory (INL) in Scoville, Idaho, and who were monitored for external radiation at the Idaho Chemical Processing Plant (CPP) (e.g., at least one film badge or TLD dosimeter from CPP) between January 1, 1975, and December 31, 1980, for a number of work days aggregating at least 250 work days, occurring solely under this employment, or in combination with work days within the parameters established for one or more other classes of employees in the Special Exposure Cohort. This designation became effective on December 22, 2017. Therefore, beginning on December 22, 2017, members of this class of employees, [[Page 3749]] defined as reported in this notice, became members of the SEC. John Howard, Director, National Institute for Occupational Safety and Health. [FR Doc. 2018-01449 Filed 1-25-18; 8:45 am] BILLING CODE 4163-19-P
![3748 Federal Register / Vol. 83, No. 18 / Friday, January 26, 2018 / Notices
Schedule I of the 1961 Single Convention on Psychotropic developing the U.S. position regarding
Convention. Substances. narcotic substances at the CND meeting.
5F–ADB is a clandestinely produced 5F–PB–22 is a synthetic cannabinoid Dated: January 23, 2018.
synthetic cannabinoid agonist. In agonist with similar effects to delta-9-
Leslie Kux,
general, adverse effects produced by tetrahydrocannabinol, one of the main
cannabinoid agonists include psychoactive components of cannabis. Associate Commissioner for Policy.
tachycardia, agitation, hallucination, Adverse effects produced by [FR Doc. 2018–01471 Filed 1–25–18; 8:45 am]
chest pain, seizure, anxiety, and acute cannabinoid agonists include BILLING CODE 4164–01–P
psychosis. 5F–ADB has been identified tachycardia, agitation, hallucination,
in overdose and/or cases involving chest pain, seizure, anxiety, acute
death attributed to their abuse. Adverse psychosis, and death. 5F–PB–22 is DEPARTMENT OF HEALTH AND
health effects reported from incidents clandestinely produced. It has been HUMAN SERVICES
involving 5F–ADB and other synthetic found laced on plant material and
Final Effect of Designation of a Class
cannabinoids have included: nausea, marketed as herbal products, and is
of Employees for Addition to the
persistent vomiting, agitation, altered smoked for its psychoactive effects.
According to the WHO, 5F–PB–22 has Special Exposure Cohort
mental status, seizures, convulsions,
loss of consciousness, and/or cardio been associated with fatal intoxications. AGENCY: National Institute for
toxicity. On April 10, 2017, the DEA On September 6, 2016, the DEA issued Occupational Safety and Health
issued a temporary scheduling order to a Final Rule to permanently place 5F– (NIOSH), Centers for Disease Control
temporarily schedule 5F–ADB, its PB–22 into Schedule I of the CSA (81 and Prevention, Department of Health
isomers, esters, ethers, salts and salts of FR 61130). As such, additional and Human Services (HHS).
isomers, esters, and ethers into permanent controls will not be
Schedule I pursuant to the temporary necessary to fulfill U.S. obligations if ACTION: Notice.
scheduling provisions of the CSA (82 FR 5F–PB–22 is controlled under Schedule
17119). As such, additional permanent II of the 1971 Convention on SUMMARY: HHS gives notice concerning
controls will be necessary to fulfill U.S. Psychotropic Substances. the final effect of the HHS decision to
obligations if 5F–ADB is controlled 4-Fluoroamphetamine (4–FA) is a designate a class of employees from the
under Schedule II of the 1971 psychoactive substance of the Idaho National Laboratory in Scoville,
Convention on Psychotropic phenethylamine and substituted Idaho, as an addition to the Special
Substances. amphetamine chemical classes and Exposure Cohort (SEC) under the Energy
AB–PINACA is a clandestinely produces stimulant effects. WHO Employees Occupational Illness
produced synthetic cannabinoid agonist reports that 4–FA is clandestinely Compensation Program Act of 2000.
approximately 1.5 times as potent as produced, and its use is associated with
FOR FURTHER INFORMATION CONTACT:
delta-9-tetrahydrocannabinol. Adverse fatal and non-fatal intoxications. 4–FA
Stuart L. Hinnefeld, Director, Division
effects produced by cannabinoid is not approved for medical use in the
of Compensation Analysis and Support,
agonists include tachycardia, agitation, United States and it is not controlled
NIOSH, 1090 Tusculum Avenue, MS C–
hallucination, chest pain, seizure, under the CSA. As such, additional
46, Cincinnati, OH 45226–1938,
anxiety, acute psychosis, and death. permanent controls will be necessary to
Telephone 877–222–7570. Information
AB–PINACA has been detected in illicit fulfill U.S. obligations if 4–FA is
requests can also be submitted by email
synthetic cannabinoid substances, and controlled under Schedule II of the 1971
Convention on Psychotropic to DCAS@CDC.GOV.
reported in cases of overdose and
hospitalizations. It has not been Substances. SUPPLEMENTARY INFORMATION:
approved for medical use in the United FDA, on behalf of the Secretary of Authority: 42 U.S.C. 7384q(b). 42 U.S.C.
States. On October 16, 2017, the DEA HHS, invites interested persons to 7384l(14)(C).
published a Final Rule to permanently submit comments on the notifications
control AB–PINACA as a Schedule I from the United Nations concerning On November 22, 2017, as provided
substance under the CSA (82 FR 47971). these drug substances. FDA, in for under 42 U.S.C. 7384l(14)(C), the
As such, additional permanent controls cooperation with the National Institute Acting Secretary of HHS designated the
will not be necessary to fulfill U.S. on Drug Abuse, will consider the following class of employees as an
obligations if AB–PINACA is controlled comments on behalf of HHS in addition to the SEC:
under Schedule II of the 1971 evaluating the WHO scheduling
Convention on Psychotropic recommendations. Then, under section All employees of the Department of
Energy, its predecessor agencies, and their
Substances. 201(d)(2)(B) of the CSA, HHS will
contractors and subcontractors who worked
UR–144 is a clandestinely produced recommend to the Secretary of State at the Idaho National Laboratory (INL) in
synthetic cannabinoid agonist. In what position the United States should Scoville, Idaho, and who were monitored for
general, adverse effects produced by take when voting on the external radiation at the Idaho Chemical
cannabinoid agonists include recommendations for control of Processing Plant (CPP) (e.g., at least one film
tachycardia, agitation, hallucination, substances under the Psychotropic badge or TLD dosimeter from CPP) between
chest pain, seizure, anxiety, acute Convention at the CND meeting in January 1, 1975, and December 31, 1980, for
psychosis, and death. UR–144 has been March 2018. a number of work days aggregating at least
detected in herbal smoking blends that Comments regarding the WHO 250 work days, occurring solely under this
are sold as herbal incense. On May 11, recommendations for control of employment, or in combination with work
daltland on DSKBBV9HB2PROD with NOTICES
days within the parameters established for
2016, the DEA issued a Final Rule to carfentanil, ocfentanil, furanyl fentanyl
one or more other classes of employees in the
permanently schedule UR–144 into (Fu-F), acryloylfentanyl (acryl fentanyl), Special Exposure Cohort.
Schedule I of the CSA (81 FR 29142). As 4-fluoroisobutyryl fentanyl (4–FIBF),
such, additional permanent controls and tetrahydrofuranylfentanyl (THF–F), This designation became effective on
will not be necessary to fulfill U.S. under the 1961 Single Convention, will December 22, 2017. Therefore,
obligations if UR–144 is controlled also be forwarded to the relevant beginning on December 22, 2017,
under Schedule II of the 1971 Agencies for consideration in members of this class of employees,
VerDate Sep<11>2014 20:14 Jan 25, 2018 Jkt 244001 PO 00000 Frm 00076 Fmt 4703 Sfmt 4703 E:\FR\FM\26JAN1.SGM 26JAN1](https://thefederalregister.org/doc/83_FR_3766/page/1.svg)
![Federal Register / Vol. 83, No. 18 / Friday, January 26, 2018 / Notices 3749
defined as reported in this notice, Adjuvant Discovery & Development for Dated: January 23, 2018.
became members of the SEC. Allergic Diseases. David Clary,
Date: February 23, 2018.
Program Analyst, Office of Federal Advisory
John Howard, Time: 11:00 a.m. to 5:00 p.m.
Committee Policy.
Director, National Institute for Occupational Agenda: To review and evaluate contract
proposals. [FR Doc. 2018–01488 Filed 1–25–18; 8:45 am]
Safety and Health.
[FR Doc. 2018–01449 Filed 1–25–18; 8:45 am] Place: National Institutes of Health, 5601 BILLING CODE 4140–01–P
Fishers Lane, Rockville, MD 20892
BILLING CODE 4163–19–P
(Telephone Conference Call).
Contact Person: Dharmendar Rathore, DEPARTMENT OF HEALTH AND
Ph.D., Scientific Review Officer, Scientific HUMAN SERVICES
DEPARTMENT OF HEALTH AND Review Program, Division of Extramural
HUMAN SERVICES Activities, Room 3G30, National Institutes of National Institutes of Health
Health/NIAID, 5601 Fishers Lane Drive, MSC
National Institutes of Health 9823, Bethesda, MD 20892–9823, 240–669– National Institute of Diabetes and
5058, rathored@mail.nih.gov. Digestive and Kidney Diseases; Notice
National Institute of Allergy and (Catalogue of Federal Domestic Assistance of Closed Meetings
Infectious Diseases; Notice of Closed Program Nos. 93.855, Allergy, Immunology,
Meetings and Transplantation Research; 93.856, Pursuant to section 10(d) of the
Microbiology and Infectious Diseases Federal Advisory Committee Act, as
Pursuant to section 10(d) of the
Research, National Institutes of Health, HHS) amended, notice is hereby given of the
Federal Advisory Committee Act, as
Dated: January 23, 2018. following meetings.
amended, notice is hereby given of the
Natasha M. Copeland,
The meetings will be closed to the
following meetings.
public in accordance with the
The meetings will be closed to the Program Analyst, Office of Federal Advisory
provisions set forth in sections
public in accordance with the Committee Policy.
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
provisions set forth in sections [FR Doc. 2018–01486 Filed 1–25–18; 8:45 am]
as amended. The grant applications and
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., BILLING CODE 4140–01–P
the discussions could disclose
as amended. The grant applications and
confidential trade secrets or commercial
the discussions could disclose
property such as patentable material,
confidential trade secrets or commercial DEPARTMENT OF HEALTH AND
and personal information concerning
property such as patentable material, HUMAN SERVICES
individuals associated with the grant
and personal information concerning
National Institutes of Health applications, the disclosure of which
individuals associated with the grant
would constitute a clearly unwarranted
applications, the disclosure of which
National Institute of Biomedical invasion of personal privacy.
would constitute a clearly unwarranted
invasion of personal privacy. Imaging and Bioengineering; Notice of Name of Committee: National Institute of
Closed Meeting Diabetes and Digestive and Kidney Diseases
Name of Committee: National Institute of Special Emphasis Panel; Fellowships in
Allergy and Infectious Diseases Special Pursuant to section 10(d) of the Digestive Diseases and Nutrition.
Emphasis Panel; NIAID Investigator Initiated Federal Advisory Committee Act, as Date: February 15–16, 2018.
Program Project Applications (P01). amended, notice is hereby given of the Time: 8:00 a.m. to 5:00 p.m.
Date: February 20, 2018. following meeting. Agenda: To review and evaluate grant
Time: 11:00 a.m. to 3:00 p.m. The meeting will be closed to the applications.
Agenda: To review and evaluate grant
public in accordance with the Place: Bethesda North Marriott Hotel &
applications.
provisions set forth in sections Conference Center, 5701 Marinelli Road,
Place: National Institutes of Health, 5601
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Bethesda, MD 20852.
Fishers Lane, Rockville, MD 20892
as amended. The grant applications and Contact Person: Jian Yang, Ph.D., Scientific
(Telephone Conference Call).
the discussions could disclose Review Officer, Review Branch, DEA,
Contact Person: Brenda Lange-Gustafson,
NIDDK, National Institutes of Health, Room
Ph.D., Scientific Review Officer, NIAID/NIH/ confidential trade secrets or commercial 7111, 6707 Democracy Boulevard, Bethesda,
DHHS, Scientific Review Program, 5601 property such as patentable material, MD 20892–5452, (301) 594–7799, yangj@
Fishers Lane, Room 3G13, Rockville, MD and personal information concerning extra.niddk.nih.gov.
20852, 240–669–5047, bgustafson@ individuals associated with the grant
niaid.nih.gov. Name of Committee: National Institute of
applications, the disclosure of which Diabetes and Digestive and Kidney Diseases
Name of Committee: National Institute of
would constitute a clearly unwarranted Special Emphasis Panel; PAR–16–034:
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated invasion of personal privacy. NIDDK Ancillary Studies to Major Ongoing
Program Project Applications (P01). Name of Committee: National Institute of Clinical Studies in Digestive Sciences (R01).
Date: February 21–23, 2018. Biomedical Imaging and Bioengineering Date: February 15, 2018.
Time: 11:00 a.m. to 5:00 p.m. Special Emphasis Panel; Mentored Career Time: 2:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant Development (K) and Conference (R13) Agenda: To review and evaluate grant
applications. Award Application Review, (2018/05). applications.
Place: National Institutes of Health. 5601 Date: March 2, 2018. Place: National Institutes of Health, Two
Fishers Lane, Rockville, MD 20892. Time: 9:30 a.m. to 5:00 p.m. Democracy Plaza, 6707 Democracy
Contact Person: Priti Mehrotra, Ph.D., Agenda: To review and evaluate grant Boulevard, Bethesda, MD 20892 (Telephone
Chief, Immunology Review Branch, Scientific applications. Conference Call).
daltland on DSKBBV9HB2PROD with NOTICES
Review Program, Division of Extramural Place: National Institutes of Health, Two Contact Person: Najma S. Begum, Ph.D.,
Activities, Room #3G40, National Institutes Democracy Plaza, Suite 920, 6707 Democracy Scientific Review Officer, Review Branch,
of Health/NIAID, 5601 Fishers Lane, MSC Plaza, Bethesda, MD 20892 (Virtual Meeting). DEA, NIDDK, National Institutes of Health,
9823, Bethesda, MD 20892–7616, 240–669– Contact Person: John P. Holden, Ph.D., Room 7349, 6707 Democracy Boulevard,
5066, pmehrotra@niaid.nih.gov. Scientific Review Officer, 6707 Democracy Bethesda, MD 20892–5452, (301) 594–8894,
Name of Committee: National Institute of Boulevard, Room 920, Democracy Two, begumn@niddk.nih.gov.
Allergy and Infectious Diseases Special Bethesda, MD 20892, (301) 496–8775, Name of Committee: National Institute of
Emphasis Panel; PHS 2018–1 Topic 54 & 55: john.holden@mail.nih.gov. Diabetes and Digestive and Kidney Diseases
VerDate Sep<11>2014 20:14 Jan 25, 2018 Jkt 244001 PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 E:\FR\FM\26JAN1.SGM 26JAN1](https://thefederalregister.org/doc/83_FR_3766/page/2.svg)
Document Created: 2018-10-26 10:03:08
Document Modified: 2018-10-26 10:03:08
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, NIOSH, 1090 Tusculum Avenue, MS C-46, Cincinnati, OH 45226-1938, Telephone 877-222-7570. Information requests can also be submitted by email to [email protected] | |
| FR Citation | 83 FR 3748 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR